Long-Term Testosterone Tx Assessed in Men With Hypogonadism and T2D – Monthly Prescribing Reference (registration)
Posted: June 13, 2017 at 3:44 am
June 11, 2017
Fasting glucose, weight, waist circumference, and body mass index were also reduced with testosterone treatment
Hypogonadal men with type 2 diabetes (T2D) who were treated with testosterone undecanoate (TU) injections demonstrated reductions in glycated hemoglobin A1c (HbA1c) and anthropometric measures, according to data presented at the 77th American Diabetes Association Scientific Sessions, June 9-13, in San Diego.
As recommended by the [American Association of Clinical Endocrinologists]/[American College of Endocrinology] guidelines for the management of obesity, it is worthwhile measuring testosterone in men with T2D, especially if they are obese, study researcher Farid Saad, PhD, with Bayer AG, Berlin, said in an interview with Endocrinology Advisor. Correcting hypogonadism by testosterone therapy will result in major improvements of the diabetic state, provided that treatment is performed long enough (ie, for life) and is adequate (ie, testosterone levels achieved are high enough).
According to Dr Saad, the registry study was initiated in 2004 to study effectiveness and safety of a new testosterone preparation that had become available in Germany that year.
This preparation is a 3-monthly injection [of TU] requiring only 4 injections per year, Dr Saad said. Injections have to be administered in the office and are always documented. This is why we know that there was a 100% adherence.
In all, the study included 321 men with hypogonadism in a urological setting. Of these men, 94 (29.3%) had T2D and were treated with the TU injections for up to 12 years. Family physicians treated the patients' T2D.
Due to reimbursement issues, roughly 50% of patients experienced temporary interruptions of TU treatment for a mean of 17 months.
Researchers examined anthropometric and metabolic parameters at every or every other visit.
Mean patient age was 60.18 years and HbA1c was poorly controlled (7.91%).
At 12 years, HbA1c decreased to 5.50.3%, which resulted in a statistically significant change vs baseline each year (P <.0001).
Results obtained during the final observation revealed that 90.4% of patients were within an HbA1c target of <7%, and 78.7% were within an HbA1c target of <6.5%.
In addition, the following metrics were also reduced from baseline: fasting glucose (4.60.7 vs 7.812.3 mmol/L; P <.0001); weight (86.66.9 vs 107.813.2 kg); waist circumference (94.52.7 vs 11410.7 cm); and body mass index (27.32.2 vs 34.14.1 kg/m2).
All improvements in anthropometric measures were statistically significant when compared with baseline (P <.0001).
Dr Saad said that he and his colleagues were initially surprised when they realized patients were losing weight in a progressive and sustained manner, because that had never before been documented in literature.
In our urological setting, we usually do not focus on weight loss in obese patients, and no detailed instructions for lifestyle modification had been provided to our patients, he said. Expectations had been that patients' sexual function, mood, and energy would improve, which is what happened.
Dr Saad added that for men with hypogonadism and obesity as well as type 2 diabetes, adequate testosterone therapy may be the most beneficial treatment possible.
The unique effect of testosterone is that it invariably increases lean body mass, which helps normalize metabolism, he said. This cannot be achieved with any other drug.
Disclosures: All 3 researchers report financial relationships with Bayer AG.
Saad F, Doros G, Yassin A. Most hypogonadal men with type 2 diabetes mellitus (T2DM) achieve HbA1c targets when treated with testosterone undecanoate (TU) injections for up to 12 Years. Poster 1144-P. Presented at: the 77th American Diabetes Association Scientific Sessions. June 9-13, 2017; San Diego, California.
See the original post:
Long-Term Testosterone Tx Assessed in Men With Hypogonadism and T2D - Monthly Prescribing Reference (registration)
- Testosterone Treatment and Fractures in Men with Hypogonadism | NEJM - nejm.org - January 20th, 2024
- Understanding Hypogonadism, Testosterone Replacement Therapy, and Prostate Cancer Risk - Medriva - January 11th, 2024
- Male hypogonadism - Patient Information - January 3rd, 2024
- Testosterone replacement therapy may not increase risk of prostate cancer among men with hypogonadism - Medical Dialogues - January 3rd, 2024
- Male Hypogonadism Market Expected to Reach $5.1 Billion by 2030 | Current Trends and Industry Analysis - EIN News - December 16th, 2023
- Hypogonadism: What Is It, Causes, Signs and Symptoms, and More - Osmosis - November 2nd, 2023
- Hypogonadism - StatPearls - NCBI Bookshelf - February 10th, 2023
- Male hypogonadism: Symptoms and treatment - PMC - PubMed Central (PMC) - February 10th, 2023
- The 'male menopause' - NHS - November 26th, 2022
- Diagnosis of Hypogonadism: Clinical Assessments and Laboratory Tests - November 1st, 2022
- Approach to the Patient With Hypogonadotropic Hypogonadism - November 1st, 2022
- Clomiphene citrate for men with hypogonadism: a systematic ... - PubMed - September 21st, 2022
- Hypogonadism in females | DermNet - September 21st, 2022
- Clomiphene citrate effects on testosterone/estrogen ratio in male ... - September 21st, 2022
- Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - Longview News-Journal - September 21st, 2022
- Male sexual health and reproductive medicine: All that glitters is not gold - Urology Times - September 21st, 2022
- The Reproductive Outcome of Women with HH in IVF - Physician's Weekly - August 20th, 2022
- Men's Health Market is Slated to Witness Tremendous Growth in Coming Years | Latest Report by IBI - Digital Journal - August 20th, 2022
- Why Can Some Medicines Increase The Risk Of Osteoporosis? - Nation World News - August 20th, 2022
- What is Erectile dysfunction (aka ED)? : Buy Kamagra to treat the ED - My MMA News.com - August 20th, 2022
- Sure Signs Your Endocrine System Isn't as Strong as it Should Be Eat This Not That - Eat This, Not That - August 11th, 2022
- What has the NFL said about Packers QB Rodgers consuming ayahuasca? - AS USA - August 11th, 2022
- Male hypogonadism: Symptoms, causes, and treatment - Medical News Today - July 8th, 2022
- Hypogonadism in Men | Endocrine Society - July 8th, 2022
- Olfactory Radioanatomical Findings in Patients With Cardiac Arrhythmias, COVID-19, and Healthy Controls - Cureus - July 8th, 2022
- Global Hormone Replacement Therapy Market Is Projected To Thriving At A CAGR of 1.51% During 2022-2028 | 120 Report Pages - Digital Journal - July 8th, 2022
- Testosterone May Aid Memory in Men With Uncontrolled Diabetes - Everyday Health - June 28th, 2022
- Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review - Cureus - June 28th, 2022
- EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody in Switzerland - Business... - April 28th, 2022
- Tucker Carlson hawks testicle tanning to boost testosterone. Experts say it may do the opposite - Salon - April 28th, 2022
- A practical guide to male hypogonadism in the primary care ... - January 1st, 2022
- Waist Circumference Is More Closely Associated with Hypogonadism than Is Hyperglycemia, Independent of BMI in Middle-Aged Men - DocWire News - January 1st, 2022
- Andrological aspects of new coronavirus infection Covid-19 - DocWire News - January 1st, 2022
- Reviewing the Top 5 Best Male Enhancement Pills in 2022 to Buy - The Daily World - January 1st, 2022
- Low Sex Drive (Hypogonadism): Symptoms, Treatment - December 22nd, 2021
- Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study - DocWire News - December 22nd, 2021
- 5 Best Testosterone Boosters to Increase Testosterone Levels in 2022 - Us Weekly - December 22nd, 2021
- Male hypogonadism | You and Your Hormones from the Society ... - November 21st, 2021
- Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle -... - November 21st, 2021
- CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) -... - November 21st, 2021
- Bio-Identical Hormone Replacement Therapy Market to Rise Due to the Increasing Applications and Wider Reach, Players Pfizer Bayer. Energy Siren -... - November 21st, 2021
- Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 - Taiwan News - October 5th, 2021
- 6 Things To Look for In a Good Testosterone Booster Supplement - The Portugal News - October 5th, 2021
- Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer - DocWire News - October 5th, 2021
- [PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell - UNLV The Rebel Yell - August 30th, 2021
- Top 6 Benefits of Testosterone Therapy Times Square Chronicles - Times Square Chronicles - August 3rd, 2021
- Hormone Replacement Therapy Market by 2027 Worldwide Growth Opportunities Recent Trends Forecast by Types and Application to 2027 The Manomet Current... - August 3rd, 2021
- 9 Ways to Increase Testosterone Naturally in 2021 - Men's Journal - August 3rd, 2021
- Testosterone Therapy for Hypogonadism Guideline Resources ... - May 26th, 2021
- Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And... - May 26th, 2021
- Trending Report of Male Hypogonadism Market Drivers, Strategies, Applications and Competitive Landscape 2026 Brockville Observer - Brockville... - May 26th, 2021
- Male menopause: Here's everything you need to know about andropause - Pulse Ghana - May 26th, 2021
- Blue Water Acquisition : Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory... - May 26th, 2021
- Hormone Replacement Therapy Market Size to Surpass US$ 36.54 Billion by 2027 with the CAGR of 8.20% The Manomet Current - The Manomet Current - May 26th, 2021
- The many effects of reproductive hormones on the brain - ESHRE - May 26th, 2021
- Hormone Replacement Therapy (HRT) Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis The Shotcaller - The Shotcaller - May 26th, 2021
- The Male Hypogonadism Market To Witness Steadfast Growth In The Next 10 Years The Courier - The Courier - May 14th, 2021
- The Male Hypogonadism Market To Ride On Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - May 14th, 2021
- Hormone Replacement Therapy Market Global Industry Scope and Growth Analysis Report 2021: Opportunity Assessment, Business Boosting Strategies, and... - May 14th, 2021
- Global Hormone Replacement Therapy (HRT) Industry Market Report 2020, Forecast Till 2027 By Type, End-use, Geography and Player The Courier - The... - May 14th, 2021
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020